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Myeloid Dendritic Cells from Human Cutaneous
Squamous Cell Carcinoma Are Poor Stimulators
of T-Cell Proliferation
Mark J. Bluth1, Lisa C. Zaba2, Dariush Moussai1, Mayte Sua´rez-Farin˜as2,3, Helen Kaporis2, Linda Fan1,
Katherine C. Pierson2, Traci R. White2, Alexander Pitts-Kiefer1, Judilyn Fuentes-Duculan2,
Emma Guttman-Yassky2, James G. Krueger2, Michelle A. Lowes2 and John A. Carucci1
To determine the phenotype and function of myeloid dendritic cells (DCs) from human cutaneous squamous-
cell carcinoma (SCC), we studied their surface marker expression and allo-stimulatory potential ex vivo. There
were abundant CD11cþ myeloid DCs, as well as TNF and inducible nitric oxide synthase (iNOS)-producing DCs,
in and around SCC tumor nests. Although myeloid DCs from SCC, adjacent non-tumor-bearing skin, and
normal skin, were phenotypically similar by flow cytometry, and there was a pronounced genomic signature of
mature DCs in SCC, they showed different T-cell stimulatory potential in an allogeneic mixed leukocyte
reaction. Myeloid DCs from SCC were less potent stimulators of allogeneic T-cell proliferation than DCs from
non-tumor-bearing skin. Culture with a DC-maturing cytokine cocktail (IL-1b, IL-6, TNF-a, and PGE2) enhanced
stimulatory potential in DCs from non-tumor-bearing skin, whereas SCC-associated DCs remained poor
stimulators of T-cell proliferation. The microenvironment associated with SCC showed expression of TGF-b, IL-
10, and VEGF-A, factors capable of suppressing the DC function. These findings indicate that CD11cþ /HLA-DRhi
DCs from SCC are mature, but are not potent stimulators of T-cell proliferation compared with phenotypically
similar DCs isolated from non-tumor-bearing skin. Identification of mechanisms responsible for suppression of
tumor-associated DCs may provide insight into the evasion of immunosurveillance by SCC.
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INTRODUCTION
Squamous-cell carcinoma (SCC) is the second most common
human cancer, affecting more than 250,000 individuals in the
United States in 2007 (Weinberg et al., 2007). In most cases,
cutaneous SCC is treated successfully by surgery; however,
it has the potential to behave aggressively and accounts for
the majority of B10,000 non-melanoma skin cancer deaths
in the United States each year (Thomas et al., 2007).
Aggressive behavior in SCC is associated with immune
compromise in the host manifested by increased incidence
in solid organ transplant recipients and individuals with
chronic lymphocytic leukemia (Vanacker et al., 2008). On
the basis of the potential for host immunity to regulate
behavior in SCC, we evaluated the immune microenviron-
ment and function of tumor-associated myeloid dendritic
cells (DCs).
Dendritic cells are professional antigen-presenting cells
that mediate innate and adaptive immunity, and may play a
key role in anti-tumor response (Steinman, 2006). Mature
DCs are identified by the expression of HLA-DR, CD86,
CD83, CD80, CD40, and other markers, and their ability to
stimulate naive T-cell proliferation. There are three major
subsets of cutaneous DCs in humans: myeloid DCs,
plasmacytoid DCs (pDCs), and Langerhans cells (Zaba
et al., 2009). There have been reports in recent years
describing tumor-associated DCs and how the numbers and
types of DCs present may serve as a prognostic indicator,
including colorectal, cervical carcinoma, esophageal SCC,
nasopharyngeal carcinoma, urinary bladder carcinoma, and
gastric carcinoma. For example, there was a significant
increase in the number of immature DCs in late-stage ovarian
carcinoma-associated ascites compared with peripheral
blood, and there was a significantly greater number of ascitic
pDCs than myeloid DCs in many of these patients
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(Siegal et al., 1999; Wertel et al., 2008a, b). These observa-
tions are typically indicative of a poor prognosis for these
patients (Zou et al., 2001). An increased presence of pDCs
has also been correlated with a poor prognosis for patients
with SCC of the head and neck (SCC of the oral and nasal
mucosa) (Hartmann et al., 2003; O’Donnell et al., 2007).
In vitro tumor antigen- or lysate-pulsed monocyte-derived
myeloid DCs can be generated for use as a specific anti-
tumor vaccine (Lee et al., 2002). For example, in a clinical
trial of 16 patients with stage IV melanoma, two complete,
three partial, and one minor response was reported after
treatment with melanoma tumor or peptide-pulsed mono-
cyte-derived myeloid DCs (Nestle et al., 1998). This strategy
has been variably successful in different cancer settings, but
supports the anti-tumor potential of these DCs (Nestle et al.,
2001; Dhodapkar et al., 2002; Pospisilova et al., 2002; Jeong
et al., 2007).
Earlier our group characterized the immune infiltrate in
basal-cell carcinoma (BCC) (Kaporis et al., 2007). That study
showed that there was an increased number of CD11cþ DCs
in the BCC tumor microenvironment compared with normal
skin, suggesting a role for DCs in this type of cancer. We have
now turned our attention to DCs in cutaneous SCC, as their
potential role and function in this human epithelial cancer
remains undefined. We studied the DC microenvironment in
human SCC and evaluated the populations, numbers,
phenotypes, and stimulatory capacity of DCs from SCC,
peritumoral non-lesional (PTNL) skin, and normal skin. We
found the following: (1) SCC is associated with appreciable
numbers of CD1aþ cells, Langerinþ cells, CD11cþ cells,
and blood-derived dendritic cell antigen (BDCA1þ ) cells; (2)
the SCC microenvironment is also associated with TNFa and
inducible nitric oxide synthase-producing myeloid DCs (TIP-
DCs); (3) CD11cþ /HLA-DRhi myeloid DCs from SCC express
maturity markers at levels similar to those from patient-
matched, site-matched PTNL skin, and normal skin from
tumor-free patients; (4) SCC is associated with a mature DC
gene expression signature; (5) myeloid DCs from SCC are
poor stimulators of allogeneic T-cell proliferation compared
with myeloid DCs from PTNL skin and normal skin; (6) and
the tumor microenvironment is associated with an increased
expression of immunosuppressive cytokines.
RESULTS
Human cutaneous SCC is associated with intratumoral CD1aþ /
Langerinþ Langerhans cells and juxtatumoral CD11cþ myeloid
DCs and BDCA2þ pDCs
Squamous-cell carcinoma and normal skin were evaluated
for the presence of DCs by immunohistochemistry. Repre-
sentative immunohistochemistry is shown for each antigen
analyzed, in normal skin and SCC and (n¼10–12 for each
group), and cell counts of all the cases are shown in
(Figure 1, right). We determined the numbers of DCs within
the SCC microenvironment on the basis of those counted
within the tumor nodules and in the papillary dermis 100mm
immediately around the tumor nodules (juxtatumoral). The
numbers of DCs in normal skin were evaluated on the basis of
those observed in the epidermis and those found in the
normal papillary dermis 100mm deep into the basement
membrane.
In SCC, CD1aþ and Langerinþ cells were infiltrating
epithelial tumor aggregates at numbers lower than those per
unit area of normal epidermis (P¼0.016 and P¼0.003,
respectively) (Figure 1a and b). There were even less
Langerhans cells in juxtatumoral skin compared with SCC
(Po0.001). There were greater numbers of CD11cþ myeloid
DCs in the juxtatumoral dermis compared with SCC tumor
nodules (Po0.001), with relatively few CD11cþ myeloid
DCs in SCCs compared with normal skin (P¼0.0012).
(Figure 1c). There were significantly greater numbers of
BDCA-1þ cells observed in both normal dermis (Po0.05)
and juxtatumoral dermis compared with SCC (Po0.005)
(Figure 1d). There were higher numbers of BDCA-2þ pDCs in
the juxtatumoral dermis compared with normal papillary
dermis (Po0.002), fewer pDCs infiltrating SCC tumor
nodules compared with juxtatumoral dermis (Po0.025), but
greater numbers of pDCs were observed in SCC
tumor nodules than in normal papillary dermis (Po0.05)
(Figure 1e).
TIP-DCs are associated with the SCC microenvironment
TNF and iNOS-producing DCs have been described in
imiquimod-treated BCC (Stary et al., 2007), and recent
studies from our group described the presence of TIP-DCs
in psoriasis (Lowes et al., 2005). Treatment of psoriasis
patients with efalizumab (anti-CD11a, Raptiva) strongly
reduces infiltration by these DCs in patients responding to
this agent, suggesting that TIP-DCs may play a role in
keratinocyte hyperproliferation. As SCC is also a condition
involving keratinocyte hyperproliferation, we wanted to
determine if TIP-DCs were present in the SCC microenviron-
ment. Triple-labeled immunofluorescence shows that there
are CD11cþ (blue) myeloid DCs that also express TNFa
(green) and iNOS (red), which seem white in color (Figure 2,
representative image).
CD11cþ /HLA-DRhi myeloid DCs from human SCC express
maturity markers
We wanted to characterize the surface phenotype of
CD11cþ myeloid DCs associated with SCC. CD11cþ /HLA-
DRhi myeloid DCs from normal skin, PTNL skin, and SCC
were evaluated for the expression of co-stimulatory and
maturity markers DC-LAMP/CD208, DC-SIGN/CD209, DEC-
205/CD205, CD83, CD86, and CD80 by flow cytometry.
Representative FACS histograms for selected markers are
shown; MFI is mean of patients studied (n¼3) (Figure 3).
Expression of DC-LAMP was slightly lower in SCC-derived
myeloid DCs (MFI¼ 1,068) compared with those from PTNL
and normal skin (MFI¼1,228 and 1,492, respectively). DC-
SIGN expression was slightly higher in myeloid DCs from
SCC (MFI¼1,938) compared with those from PTNL skin, but
lower than those from normal skin (MFI¼ 1,759 and 2,278,
respectively). Myeloid DCs from SCC expressed greater levels
of DEC-205 (MFI¼ 32,963) than PTNL and normal skin
(MFI¼ 27,513 and 18,616, respectively). SCC-associated
myeloid DCs expressed CD83 (MFI¼2,963), but at slightly
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lower levels than those from site-matched PTNL and normal
skin (MFI¼3,959 and 3,527, respectively). Myeloid DCs
from SCC expressed higher levels of CD86 (MFI¼788)
compared with site-matched PTNL and normal skin
MFI¼566 and 414, respectively). Myeloid DCs from SCC
express lower levels of CD80 (MFI¼ 283) than those from
site-matched PTNL and normal skin (MFI¼ 387 and 662,
respectively). On the basis of these results it seems that SCC-
associated myeloid DCs achieved slightly increased expres-
sion of maturation marker DEC-205 and co-stimulatory
molecule CD86 than PTNL skin and normal skin, but all
the three groups have a similar overall phenotype.
SCC is associated with a mature DC gene expression signature
The genomic signature of DC genes was analyzed in our
samples, as the surface phenotype of myeloid DC in SCCs
was relatively mature and similar to DCs in the adjacent
PTNL skin. The fold change for DC genes in four lists was
evaluated, as described in Material and Methods. Figure 4
shows the mean fold change of DC gene sets for SCC versus
normal skin (black bars) and PTNL versus normal skin (gray
bars). Mature DC genes showed increased mean expression
in SCC (Po0.004). In PTNL versus normal skin, all gene lists
showed increased expression (Po0.05). The significance of
those findings was also tested using gene set enrichment
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Figure 1. Human cutaneous squamous-cell carcinoma (SCC) is associated with intratumoral CD1aþ /Langerinþ Langerhans cells, juxtatumoral CD11cþ
myeloid DCs, and BDCA2þ plasmacytoid dendritic cells (DCs). Representative immunohistochemistry (left) and summary data with median cell count values
of (a) CD1a, (b) Langerin, (c) CD11c, (d) BDCA-1, and (e) BDCA-2 cells in normal skin, SCC, and juxtatumoral skin. Asterisks (*) indicate significance, where
*Po0.05, **Po0.01 and ***Po0.005. Bar¼ 100 mm.
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analysis (GSEA) (Table 1). DC gene expression was signifi-
cantly enriched in PTNL skin compared with normal skin
(Hohenkirk_DC_Up, P¼ 0.024), whereas in SCC, enrichment
of mature DC genes is increased (NES (normalized enrich-
ment score) ¼1.25), but did not reach statistical significance
(P¼0.12). Overall, these data indicate DC gene activation in
and around human SCC.
DCs from SCC are poor stimulators of allogeneic T-cell
proliferation
As CD11cþ /HLA-DRhi DCs from SCC and PTNL skin
expressed similar levels of maturity markers, we measured
the capacity of these cells to stimulate allogeneic T-cell
proliferation in an allogeneic mixed leukocyte reaction (allo-
MLR). DCs were isolated from SCC and adjacent PTNL skin
and co-cultured with allogeneic T cells for 8 days.
Representative dot plots for CFSE (Carboxyfluorescein diace-
tate, succinimidyl ester) versus CD3 are shown for controls
and each condition, and the gate for proliferating cells is
shown in Figure 5a. A summary of all MLR data is shown in
Figure 5b, and results are tabulated in Table 2. On day 8,
allogeneic T-cell proliferation determined by CFSE dilution
showed that SCC-derived myeloid DCs were two- to
threefold weaker stimulators of allogeneic T-cell proliferation
compared with DCs derived from matched PTNL, but they
were similar to normal skin (Figure 5a). Treatment with a
iNOS TNF
CD11c
iNOS = red
TNF = green
CD11c = blue
TNF
CD11c
iNOS
Figure 2. TNF-a and inducible nitric oxide synthase (iNOS)-producing dendritic cells (TIP-DCs) are found within the squamous-cell carcinoma (SCC)
microenvironment. Representative triple-labeled immunofluorescence reveals the presence of CD11cþ myeloid DCs (blue) that also express TNF-a (green) and
iNOS (red). Triple positive cells appear white (inset higher fourfold higher magnification). Monochromatic images in upper panel, single pseudocolor controls in
middle panel, merged image below. Bar¼ 100 mm.
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maturation cocktail containing cytokines including: IL1b, IL6,
TNFa, and PGE2, increased stimulatory potential of peritu-
moral DCs slightly, but was less effective in enhancing
stimulatory potential of DCs from SCC than normal skin
(Figure 5, right lower three panels).
The SCC microenvironment is associated with an increased
expression of cytokines that may suppress DC function
As myeloid DCs from SCC display maturity markers, yet lack
appreciable allostimulatory potential, the level of expression
of soluble immunosuppressive factors, IL-10, TGF-b, and
VEGF-A, was evaluated in the tumor microenvironment
compared with PTNL and normal skin. The mean IL-10
mRNA expression was increased in both SCC and PTNL skin
compared with normal skin. However, these increases
were not significant (P¼0.086 and P¼ 0.199, respectively)
(Figure 6, left panel). The mean expression of TGF-b mRNA
was significantly increased in SCC compared with both PTNL
and normal skin (Po0.027 and Po0.001, respectively)
(Figure 6, middle panel) and in PTNL compared with normal
skin (Po0.001). There was also a significantly higher mean
level of expression of VEGF-A mRNA in both SCC and PTNL
skin compared with normal skin (Po0.001 for both) and the
mean level of VEGF-A mRNA was significantly increased in
PTNL skin compared with SCC (Po0.041) (Figure 6, right
panel).
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Figure 3. Phenotypically mature myeloid dendritic cells (DCs) are present in Normal, Peritumoral (PTNL) and squamous-cell carcinoma (SCC)–bearing skin.
CD11cþ /HLA-DRhi cells from normal skin, peritumoral non-lesion (PTNL), and SCC express maturation markers DC-LAMP, DC-SIGN, DEC-205, and
co-stimulatory markers CD83, CD86, and CD80. There were slightly increased DEC-205 and CD86 in myeloid DCs from SCC. Blue lines represent isotype
control; mean fluorescence intensity (MFI) value is shown in the upper right hand corner of each histogram (n¼3).
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Figure 4. Mature myeloid dendritic cell (DC) gene signature is present in
squamous-cell carcinoma (SCC) and peritumoral skin. The mean fold change
of published DC gene sets for SCC versus normal skin (black bars) and
peritumoral non-lesion (PTNL) versus normal skin (gray bars). Mature DC
genes showed increased mean expression in SCC (Po0.004). In PTNL versus
normal skin, all gene lists showed increased expression (Po0.05). Data
expressed as mean log fold change±standard error.
Table 1. Gene set enrichment analysis (GSEA) of DC
gene expression in SCC and PTNL skin compared with
normal skin
PTNL versus normal SCC versus normal
DC gene lists NES P-value NES P-value
Hohenkirk_DC_Up 1.61 0.024 0.94 0.510
Lindstedt_DC_Up 1.54 0.059 0.99 0.464
Mature DC 1.34 0.083 1.25 0.122
Immature DC 0.98 0.500 0.82 0.780
DC, dendritic cell; NES, normalized enrichment score; PTNL, peritumoral
non-lesional; SCC, squamous-cell carcinoma.
DC gene expression was compared amongst published DC gene lists
(Haider et al., 2007)-(Le Naour et al., 2001). DC gene expression was
significantly enriched in PTNL skin compared with normal skin
(Hohenkirk_DC_Up, P=0.024), whereas in SCC, enrichment of mature
DC genes is increased (NES=1.25), but did not reach statistical
significance (P=0.12).
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DISCUSSION
Several findings stand out from the results reported here: (1)
human cutaneous SCC was associated with CD11cþ and
BDCA1þ cells in the juxtatumoral dermis; (2) CD1aþ and
Langerinþ Langerhans cells were found in epithelial tumor
nests, but at lower concentrations per unit area than normal
epithelium; (3) the SCC microenvironment was associated
with CD11cþ TIP-DCs; (4) CD11cþ /HLA-DRhi myeloid DCs
from SCC and site-matched peritumoral skin express funda-
mentally similar levels of maturation markers; (5) expression
array analysis indicated a mature DC pathway signature in
SCCs; (6) myeloid DC from SCC were poor stimulators of
allogeneic T-cell proliferation compared with DCs from
adjacent PTNL skin; (7) treatment with maturation cytokines
enhanced stimulatory potential of DCs from normal skin and
peritumoral skin, but had less effect on DCs from SCC; and (8)
the SCC tumor microenvironment was associated with an
increased expression of immunosuppressive cytokines.
Thus, our initial characterization of the myeloid DCs in
SCC showed that, although these DCs were as phenotypically
mature as normal skin DCs, they were impaired in their
ability to upregulate their allostimulatory capacity compared
with those obtained from normal skin. The difference in
allostimulation is most noticeable when the myeloid DCs
from both SCC and normal skin were treated with maturing
cytokines. Similarly, Zaba et al., (2007b) described ‘‘steady-
state’’ myeloid DCs found in normal skin are not fully mature,
but may become so when immunologically or otherwise
challenged. We also showed that, although located only
2–5mm from the tumor margin, DCs derived from PTNL skin
were consistently better stimulators of allogeneic T cells than
those derived from SCC. Hence, although myeloid DCs from
SCC and PTNL skin expressed similarly intermediate level of
9691.8
0.38 2.46
66.2 81.6
4.58 39.7
3.15 10.3
0.96 2.62
+CYT
T cells +
CD3/28 Beads
T cells
(Unstimulated)
MoDCs
Normal
PTNL
SCC
CFDA
CD
3
SC
C
PT
NL
No
rm
al
No
rm
al 
+ C
YT
PT
NL
 + 
CY
T
SC
C +
 CY
T
%
 liv
e 
T 
ce
lls
 p
ro
life
ra
tio
r
0
10
20
30
40
50
Figure 5. Myeloid dendritic cells (DCs) from squamous-cell carcinoma
(SCC) are poor stimulators of allogeneic T cells. (a) Representative FACS dot
plots of T-cell proliferation with various stimuli, and (b) summary of results
with median values indicated. CD3/CD28 beads and monocyte-derived
immature DCs (MoDC) stimulate robust T-cell proliferation; unstimulated
T cells do not proliferate. Myeloid DCs sorted from normal skin and SCC
minimally stimulate T-cell proliferation, and peritumoral non-lesion skin
(PTNL) myeloid DCs are slightly more allo-stimulatory. Myeloid DCs
from normal skin were most responsive to cytokine cocktail containing
IL-1b, IL-6, TNF, and PGE2 (þCYT). Percent live, proliferating T cells
indicated in gate.
Table 2. Percent live T-cell proliferation in allo-MLR
induced by myeloid DCs
SCC SCC+CYT PTNL PTNL+CYT
PT 1 0.78 1.26 9.57 7.33
PT 2 2.10 3.10 6.71 12.40
PT 3 5.56 18.10 46.6 43.15
PT 4 6.90 10.40
NORMAL NORMAL+CTY
N1 2.15 20.3
N2 18.20 41.5
N3 3.10 20.9
allo-MLR, allogeneic mixed leukocyte reaction; +CYT, myeloid DCs
cultured with cytokine cocktail; DCs, dendritic cells; N, normal skin
samples; PTNL, peritumoral non-lesional skin; PT, patient; SCC,
squamous-cell carcinoma.
Chart illustrates representative values for MLRs carried out using myeloid
DCs from SCCs and patient-matched PTNL skin and normal skin both with
(+CYT) and without DC-maturing cytokines.
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maturity, they differed in allogeneic T-cell stimulatory
capacity.
However, there was an abundant genomic signature of
both immature and mature DCs in SCC lesions, therefore we
consider that the tumor may be secreting factors causing this
paralysis. Candidates include IL-10 and TGF-b, both of which
were elevated in lesional tissue and sun-damaged skin
adjacent to the tumor. Both these cytokines may have an
immunosuppressive role (Steinbrink et al., 1999; Mimura
et al., 2007). VEGF-A, whereas not increased in SCC, was
increased in peritumoral skin compared with normal skin,
and has been reported to decrease the stimulatory function of
mature monocyte-derived myeloid DCs (Mimura et al.,
2007). This observation is noteworthy because it may help
explain why myeloid DCs from peritumoral skin still
significantly lack stimulatory capacity compared with those
from normal skin, even when treated with maturing
cytokines. VEGF-A isoforms are designated on the basis of
their peptide lengths, the most well studied being VEGF-A121,
VEGF-A165, and VEGF-A189, all of which have pro-angio-
genic effects. However, Ladomery et al. have described the
expression of another class of VEGF-A isoforms derived from
alternative 30 splicing of the mRNAs that corresponds to the
above-mentioned VEGF-A proteins (Ladomery et al., 2007).
These splice variants produce peptides of nearly identical
lengths (that is, VEGF-A121b, VEGF-A165b, and VEGF-A189b),
but have anti-angiogenic effects. The splice variant mRNAs
for VEGF-A165 and VEGF-A165b produce peptides that are
identical except for the last 6 C-terminal amino acids. As the
commercially available reverse transcriptase (RT)-PCR
primer-probe set we used may identify both pro- and
anti-angiogenic isoforms of VEGF-A, it may be that the
increased expression of VEGF-A in normal skin represents the
anti-angiogenic isoform and the level of expression of
VEGF-A in SCC represents the level of the pro-angiogenic
isoform. Bates et al. address this distinction for a number of
normal tissues in their study (Bates et al., 2002). We are
currently working to define differential VEGF-A isoform
expression in the SCC microenvironment. Thus tumors may
develop many mechanisms by which they slow or disable
myeloid DC anti-tumoral activity.
In addition to tumor-derived factors that may impair local
DC function, there are other leukocytes that seem to promote
tumor growth, including immature DCs, pDCs, regulatory
DCs, and regulatory T cells (Enk et al., 1997; Berger et al.,
2002; Dauer et al., 2003; Talmadge et al., 2007). There is
also a heterogeneous population of myeloid cells that may
have tumor-promoting functions, termed myeloid-derived
suppressor cells (MDSCs). This group of cells includes
granulocytic, macrophage, DC, and early myeloid progeni-
tors (Young and Lathers, 1999; Apolloni et al., 2000;
Kusmartsev and Gabrilovich, 2005; Zea et al., 2005). In
humans, they are identified as CD3, CD11bþ , CD14,
CD19, CCD33þ , CD56, and HLA-DR. MDSCs can
inhibit T-cell activation and antigen-specific proliferation
(Movahedi et al., 2008). Angiogenic factors such as
plasminogen activator inhibitor 1 correlated with an in-
creased number of immature DCs and MDSCs in the blood of
patients with advanced malignancies (Osada et al., 2008).
The mechanisms responsible for immunosuppressive func-
tions of MDSC include production of reactive oxygen
species, NO, L-arginine metabolism, and cytokines. MDSCs
have been shown to prevent the development of antigen-
specific T cells by decreasing the proximal concentration of
L-arginine through the arginase and NOS pathways (Bronte
et al., 2003). VEGF has also been directly correlated with
myeloid DC expansion (Ohm and Carbone, 2001). Therefore,
not only can tumor cells modulate the immune system to
escape immunosurveillance, but they can also take control of
immune cells and use them to actively interfere with
continued efforts by the immune system to destroy it.
In our study, we have observed the presence of TIP-DCs
around the SCC tumor nests. Previously we described TIP-
DCs in the common inflammatory skin disease psoriasis
(Lowes et al., 2005). These cells were first described in a
murine model of Listeria monocytogenes infection (Serbina
et al., 2003), and their presence in the spleen of infected mice
was CCR2-dependent. We have since determined that these
TIP-DCs are part of a group of myeloid dermal DCs that we
have termed ‘‘inflammatory’’ DCs. These cells are character-
ized by the following surface markers: CD11cþ , HLA-DRhi,
and they are BDCA-1/CD1c, unlike the resident myeloid
DCs found in normal skin in steady state, which are BDCA-1/
CD1cþ (Zaba et al., 2007b, 2009). These inflammatory DCs
are able to produce cytokines and inflammatory mediators
such as TNF, iNOS, IL-20, and IL-12/23p40 (Wang et al.,
2006; Zaba et al., 2007a, 2008a, 2009). They are also able
to induce allogeneic T-cell proliferation, and Th1- and
Th17-cell polarization (Zaba et al., 2008a). Thus, although
capable of classic antigen-presenting function ex vivo, we
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Figure 6. IL-10, TGF-b, and VEGF-A were expressed in the squamous-cell carcinoma (SCC) microenvironment. The relative mRNA expression of (a) IL-10
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hypothesize that the main role of these inflammatory DCs in
the skin may be that of pro-inflammatory cytokine production
critical in the pathogenesis of psoriasis.
Stary et al. were the first to show that TIP-DCs were present
in a tumor model, in BCCs after treatment with the TLR7/8
agonist imiquimod (Stary et al., 2007). As they did not find
staining of these tumors for these markers before imiquimod,
it was presumed that the treatment induced these TIP-DCs. In
an effort to further characterize the CD11cþ myeloid DCs
surrounding the SCCs, we carried out immunofluorescence
for TNF and iNOS, expecting an absence of such mediators. It
was a surprise to find abundant dermal TNF- and iNOS-
producing CD11cþ cells. We have earlier shown increased
iNOS mRNA in SCCs (Haider et al., 2006).
This finding led us to consider the role of these TIP-DCs,
and their relationship to the myeloid DCs we obtained for
functional assays. The gating strategy for obtaining cells from
the SCC tissue for T-cell stimulating capability was CD11cþ /
HLA-DRþ , and it is not possible to retrospectively assess if
some of the myeloid DCs obtained from the single cell
suspensions were making TNF-a and iNOS. We will address
this question in future studies. These TIP-DCs could be part of
the host inflammatory response to the tumor, to try and
induce a pro-inflammatory environment and stimulate
regression. Current dogma is that certain inflammatory
leukocytes are good prognostic indicators, reviewed by
Talmadge, 2007. For example, mature DCs, IFN-g primed
macrophages, and Th1 cells, are all leukocyte populations
that may contribute to tumor regression. Both the human
clinical situations in which TIP-DCs have been described to
date are in the setting of reduced cancer: in psoriasis, in
which there is little cutaneous malignancy and in imiquimod-
induced regressing BCCs. We have not quantitated these cells
or examined sufficient SCCs to conclude this, but it is
possible that TIP-DCs are also trying to induce tumor
regression, but are impaired in their efforts by immunosup-
pressive factors produced by the tumor.
Alternatively, it is possible that the TIP-DCs fall into the
group of MDSC, as one of their defining mediators is iNOS
and subsequently NO. This short-lived mediator can have
immunosuppressive effects such as inhibiting the prolifera-
tion of activated helper T cells (Huang et al., 1998; van der
Veen et al., 2000). However, against classifying the TIP-DCs
as myeloid DCs is the fact that TIP-DCs are likely to be HLA-
DRþ , and MDCS were defined as HLA-DR. Future
investigations will further evaluate the phenotype and
function of these TIP-DCs, and how they fit into our working
model of resident and ‘‘inflammatory’’ dermal DCs (Zaba
et al., 2009), as well as their contribution to tumor growth or
suppression.
Some of the major causes for the lack of immunogenicity
in cancer are associated with hypoactive DCs and the
presence of regulatory T cells (Ishibashi et al., 2006; Kono
et al., 2006; Larkin et al., 2006). The cytokine milieu in the
tumor microenvironment may help drive these associative
factors, but seems to depend on the concentration of each
cytokine at any given time. In addition, expression of the
Th17-associated cytokine, IL-22, may contribute to the
hyperproliferation of keratinocytes in SCC as has been
described in psoriasis (Chan et al., 2006; Fitch et al., 2007;
Nickoloff, 2007; Lowes et al., 2008; Ma et al., 2008). Taken
together, all of these conditions pose a formidable challenge
for standard chemotherapeutic and biotherapeutic modalities
in the treatment of malignant cancers of the skin. However, a
better understanding of the cytokine milieu, DC function, and
tumor evasion of immune responses may eventually lead to
better immunomodulatory drugs and immune-based vaccine
therapies applicable to carcinomas not amenable to standard
treatments.
MATERIALS AND METHODS
Approval from the Weill Cornell Medical College Institutional
Review Board and written informed consent was obtained before
enrolling patients to participate in this study, and the study was
conducted with strict adherence to the Declaration of Helsinki
Principles.
Samples used for IHC
Cutaneous SCC samples were obtained during Mohs micrographic
surgery. Tumors were obtained from the head and neck, trunk and
extremities. In addition, normal specimens were obtained by 3-mm
punch biopsies from non-sun exposed areas of patients without skin
cancer. Some of these samples may have been used in earlier studies
as normal controls (Guttman-Yassky et al., 2007).
Immunohistochemistry
Frozen tissue sections were stained as described earlier (Kaporis
et al., 2007). We stained sections with hematoxylin (Fisher, Fair
Lawn, NJ) and eosin (Shandon, Pittsburgh, PA) and with purified
mouse anti-human monoclonal antibodies to CD1a and CD11c, (BD
Pharmingen, San Diego, CA; all 1:100), Langerin, (Immunotech,
Marseille, France 1:50), BDCA-1/CD1c and BDCA-2/CD303 (clones
AD5-8E7 and AC144, respectively, Miltenyi Biotech, Auburn, CA,
both 1:100). Biotin-labeled horse anti-mouse antibody (Vector
Laboratories, Burlingame, CA) was amplified with avidin–biotin
complex (Vector Laboratories) and developed with chromogen
3-amino-9-ethylcarbazole (Sigma Aldrich, St Louis, MO). Counter-
staining was carried out with light green (Sigma Aldrich). Appro-
priate isotype controls were used.
Image analysis
Tumor-bearing skin and non-tumor-bearing skin adjacent to excised
tumor (n¼ 10–19), and normal skin from volunteers (n¼ 10) were
evaluated for the expression of a panel of surface markers by
immunohistochemistry. The regions examined within SCC samples
were designated as ‘‘tumor’’ and ‘‘juxtatumoral dermis’’ (the dermis
immediately surrounding the tumor). The regions examined within
normal skin samples were designated as normal epidermis and
normal (papillary) dermis. Normal papillary dermis and juxtatumoral
dermis were compared in this study on the basis of the structural
similarities between these regions. Positive cells were counted
manually, and area measures were computed by computer-assisted
image analysis, National Institutes of Health software (NIH IMAGE
6.1 and IMAGE J). Cell counts per unit area (mm2 100,000) were
determined within normal epidermis, normal papillary dermis
(100mm deep to the epidermis), SCC epithelial aggregates, and
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juxtatumoral dermis (100 mm circumferential to tumor nodules). In
the all cases, tumor sections with representative response were
selected for analysis.
Immunofluorescence
Frozen sections of SCC were fixed in 100% acetone for 5minutes
(n¼ 5). Non-specific staining was blocked with 5% normal goat
serum and 5% normal chicken serum (both from Vector Labora-
tories). Tissue was then stained overnight at 41C with two primary
antibodies: (1) murine anti-TNF-FITC (clone 6401.1111, 1:10, BD
Biosciences, San Jose, CA), and (2) iNOS affinity-purified rabbit
antibody (N-20, 1:20, Santa Cruz, Santa Cruz, CA). The following
day, slides were washed and labeled with two secondary antibody
conjugates for 30minutes at room temperature: (1) goat anti-FITC-
Alexa-488 and (2) anti-rabbit Alexa-594. Sections were blocked with
10% mouse serum for 30minutes and stained overnight with murine
anti-CD11c (B-ly6, 1:100, BD Pharmingen) labeled with Zenon
Alexa Fluor-647 Mouse IgG1. All amplification/detection systems
were from Invitrogen/Molecular Probes (Eugene, OR). Images were
acquired using appropriate filters of a Zeiss Axioplan 2 widefield
fluorescence microscope (Carl Zeiss Microimaging Inc., Thornwood,
NY) fitted with a PlanNeofluar  10/0.30 NA objective lens and a
Hamamatsu Orca ER CCD camera (Hamamatsu, Bridgewater, NJ)
controlled by MetaVue software (MDS Analytical Technologies,
Downington, PA). TNF was visualized using a FITC filter set (Carl
Zeiss Microimaging Inc., Thornwood, NY), iNOS with a Texas red
filter set (Carl Zeiss Microimaging Inc., Thornwood, NY), and CD11c
with a Cy5 filter set (Carl Zeiss Microimaging Inc., Thornwood, NY).
Images in the figure are presented both as single monochrome images,
and in pseudocolor (green, red, and blue) located above the merged
image, so that one can appreciate the localization of markers on
similar or different cells. Red and green overlapping cells seem yellow
in color; red and blue seem purple; and green and blue seem aqua;
cells labeled with all three stains seem white. Inset shows triple-labeled
cell at higher magnification (fourfold increase in image size). Dermal
collagen fibers gave green auto-fluorescence. Bar¼ 100mm.
Skin sample preparation for flow cytometry analysis and FACS
Squamous-cell carcinoma tumors and sight-matched peritumoral skin
were obtained at surgery, and normal skin was obtained as the
discarded product of abdominoplastic surgery. Subcutaneous fat was
excised, and the remaining tissue was washed thrice with phosphate-
buffered saline (PBS) and then once with PBS containing 10%
gentamicin reagent solution (Invitrogen, Carlsbad, CA). Both the
dermal and epidermal layers were heavily scored with a scalpel, then
transferred to fresh RPMI 1640 (Invitrogen) supplemented with 10%
pooled human serum (Mediatech Inc., Manassas, VA), 0.1% gentami-
cin reagent solution (Invitrogen), 1% penicillin–streptomycin solution
(Sigma Aldrich), and 1% 1M HEPES buffer (Sigma Aldrich). The tissue
was incubated for 72hours in 5% CO2 at 371C. The supernatant was
collected and filtered with 40mm cell strainers (BD Biosciences) yielding
a single cell suspension. Cells were then either used immediately (for
MLR) or frozen in RPMI 1640 (Invitrogen) with 50% pooled human
serum and 10% DMSO (ATCC, Manassas, VA) for FACS.
Flow cytometry
Cellular suspensions (SCC and matched PTNL n¼ 3; normal skin
n¼ 3) were washed once with PBS and then stained with
AquaMarina Live/Dead cell detection according to the manufac-
turers instructions (Molecular probes/Invitrogen) and then stained
with the following anti-human, mouse monoclonal antibodies: HLA-
DR—Alexa Fluor 700 (L243, IgG2a, 1:50; BioLegend, San Diego,
CA), CD11c—PE-Cy7 (3.9, IgG1, 1:20; BioLegend), dendritic cell
lysosome-associated membrane protein—PE (DC-LAMP/CD208-PE)
(I10-1112, IgG1, 1:20; BD Pharmingen, San Jose, CA), dendritic cell-
specific intercellular adhesion moleule-3-grabbing non-integrin—
PerCP-Cy5.5 (DC-SIGN/CD209-PerCP-Cy5.5) (DCN46, IgG2b,
1:20; BD Biosciences), DEC-205/CD205-Alexa 647 (MMRI-7,
IgG1, 1:33; BD Pharmingen), CD80-PE (L307.4, IgG1, 1:20; BD
Biosciences), CD86-Pacific Blue (IT2.2, IgG2b, 1:50; BioLegend),
and CD83-APC (Michel-19, IgG1, 1:33; BD Pharmingen). In brief,
cells were stained in a total volume of 100 ml for 30minutes at 41C,
washed with FACS wash (PBS with 0.2% wt/vol BSA and 0.1% wt/
vol sodium azide), and resuspended in 1.3% formaldehyde (Thermo
Fisher Scientific, Waltham, MA) in FACS wash. Samples were
acquired using a flow cytometer (LSR II; BD Biosciences) and
analyzed with FlowJo software (TreeStar Inc., Ashland, OR).
Appropriate isotype controls were used.
Mixed leukocyte reaction (MLR)
Single-cell suspensions of dermal cell crawl-outs were stained with
mouse anti–human, CD11c-PE (S-CHL-3, IgG2b, 1:20, BD Bios-
ciences) and HLA-DR—Alexa Fluor 700 monoclonal antibodies, and
sorted on a FACSAria (BD Biosciences) using a low-pressure setting
(n¼ 3–4). A population of CD11cþ /HLA-DRhi cells was collected
and a post-sort collection was carried out to confirm its purity. T cells
were obtained from a normal volunteer by treatment of while blood
with RosetteSep T cell enrichment cocktail as per the manufacturers
instructions (Stem Cell Technologies, Vancouver, BC, Canada), then
subjected to density centrifugation over Ficoll-Paque Plus (Amer-
sham Biosciences, Piscataway, NJ), and subsequently labeled with
10 mm CFSE using the Vybrant CFDA SE Cell Tracer Kit (Invitrogen/
Molecular Probes) in PBS with 0.1% BSA for 15minutes at 371C. We
have adapted a modified allo-MLR described in Zaba et al. (2007b).
Briefly, CFSE-labeled T cells were co-cultured with sorted CD11cþ /
HLA-DRhi cells for 8 days with and without cytokines for maturing
DCs ex vivo (IL-1b, IL-6, TNF-a, and PGE2), at a ratio of 1:50. T cells
alone were used as a negative control. T cells cultured with CD3/
CD28-coated beads (Dynal, Invitrogen) or immature monocyte-
derived myeloid DCs were used as positive controls. The process for
making monocyte-derived DCs was described earlier (Dhodapkar
et al., 2002; Lee et al., 2002). T-cell proliferation was analyzed on
day 8 after sorting. The cultures were harvested, stained with 250 ng/
ml propidium iodide (BD Pharmingen (catalog #51-66211E)) to label
dead cells and CD3-APC (BD Biosciences) for 20minutes at room
temperature. Propidium iodide-negative cells were gated and then
plotted as CFSE versus CD3þ cells, in which proliferating cells
diluted their content of CFSE and moved to the left of the non-
proliferating cells. The CFSE-low cells were quantified as a
percentage of proliferating cells in the culture.
RNA Isolation
Total RNA isolation and RT-PCR reactions were carried out as
described earlier (Kaporis et al., 2007). Briefly, SCC tumor samples,
removed at Mohs surgery (n¼ 10–12), and patient-matched site-
matched PTNL skin (n¼ 10–12) were obtained at the time of repair
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after clear margins were achieved. Normal skin was obtained as
the waste from abdominoplastic surgery (n¼ 4). All samples were
snap-frozen and stored in liquid nitrogen. Individual frozen samples
were placed in 1ml of room temperature RLT Lysis buffer with 1%
b-mercaptoethanol (Qiagen, Valencia, CA) and immediately homo-
genized at full power for 30 seconds using a PowerGen 1000
homogenizer (Fisher Scientific, Pittsburgh, PA). Homogenates were
sonicated on ice for 20 seconds at full power. DNA was removed
with on-column DNAse digestion using an RNAse-free DNAse Set
(Qiagen). RNA was isolated using the RNeasy Mini Kit (Qiagen)
according to manufacturer’s recommendations. Total RNA concen-
tration and purity was evaluated using an Ultraspec 2100 pro-
spectrophotometer (Amersham Biosciences).
RT-PCR
The primers and probes used for IL-10 (Hs00174086_m1), TGF-b
(Hs99999918_m1), and VEGF-A (Hs00900054_m1) were TaqMan
RT-PCR individual assays designed by Applied Biosystems (Foster
City, CA). The sequences of the primers and probe for human
acidic ribosomal protein (HARP) are: HARP-forward, CGCTGC
TGAACATGCTCAA, HARP-reverse, TGTCGAACACCTGCTGGA
TG; HARP-probe, 6-FAM-TCCCCCTTCTCCTTTGGGCTGG-TAMRA
(GenBank accession no. NM-001002). The RT-PCR reaction was
carried out using 5ng total RNA and EZ PCR Core Reagents (Applied
Biosystems) according to the manufacturer’s directions. The samples
were amplified and quantified on an Applied Biosystems PRISM
7900 HT using the following thermal cycler conditions: 2minutes at
501C, 30minutes at 601C, 5minutes 951C; and 40 cycles of
15 seconds at 951C followed by 60 seconds at 601C. Each sample
and gene was normalized to the HARP gene, a housekeeping gene.
The data were analyzed and samples were quantified by the software
provided with the Applied Biosystems PRISM 7900 HT.
DC maturity pathway analysis
Squamous-cell carcinoma microarray data have been published earlier
(Haider et al., 2007). We wanted to evaluate the fold change for DC
genes published in four lists: (1) immature DC upregulated genes
(Haider et al., 2007), (2) mature DC upregulated genes (Haider et al.,
2007), (3) Lindstedt (Lindstedt et al., 2002), and (4) Hohenkirk
monocyte-derived DCs ‘‘up’’ (Le Naour et al., 2001). These lists were
similar: in total, 10 of the genes in the Hohenkirk list were in the
immature DC list (Po0.0001) and 9 of the Lindstedt and 11 of the
Hohenkirk were in the mature DC list (Po0.0001 for both) (analyzed
in http://www.broad.mit.edu/gsea/index.jsp). We also tested the
significance of gene expression findings using gene set enrichment
analysis (Subramanian et al., 2007). Gene set enrichment analysis is a
method that determines whether an earlier defined set of genes (in our
case the DC gene lists) shows statistically significant differences
between two biological states (skin samples, for example SCC versus
normal skin) using rank statistics. If the upregulated genes in the DC list
are ranked high in ‘‘SCCs versus normal fold change’’, the ES score will
be near 1, if the opposite effect happens, then the value approaches
1. As we were working with a several lists, an NES allowed us to
compare the enrichment score between lists.
Statistical analysis
Statistical comparisons of relative cell counts per mm2  100,000
was carried out using an ANOVA (analysis of variance) mixed model
in log2 scale, with Po0.05 considered significant. Statistical
comparisons of mRNA expression levels was carried out also using
the same ANOVA mixed model in log2 scale with Po0.05
considered significant.
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